Valanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Valanafusp alfa. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Valanafusp alfa. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Valanafusp alfa. |
| Estrone | Estrone may increase the thrombogenic activities of Valanafusp alfa. |
| Estradiol | Estradiol may increase the thrombogenic activities of Valanafusp alfa. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Valanafusp alfa. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Valanafusp alfa. |
| Mestranol | Mestranol may increase the thrombogenic activities of Valanafusp alfa. |
| Estriol | Estriol may increase the thrombogenic activities of Valanafusp alfa. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Valanafusp alfa. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Valanafusp alfa. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Valanafusp alfa. |
| Tibolone | Tibolone may increase the thrombogenic activities of Valanafusp alfa. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Valanafusp alfa. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Valanafusp alfa. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Valanafusp alfa. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Valanafusp alfa. |
| Zeranol | Zeranol may increase the thrombogenic activities of Valanafusp alfa. |
| Equol | Equol may increase the thrombogenic activities of Valanafusp alfa. |
| Promestriene | Promestriene may increase the thrombogenic activities of Valanafusp alfa. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Valanafusp alfa. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Valanafusp alfa. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Valanafusp alfa. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Valanafusp alfa. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Valanafusp alfa. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Valanafusp alfa. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Valanafusp alfa. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Valanafusp alfa. |
| Formononetin | Formononetin may increase the thrombogenic activities of Valanafusp alfa. |
| Estetrol | Estetrol may increase the thrombogenic activities of Valanafusp alfa. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Valanafusp alfa. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Valanafusp alfa. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Valanafusp alfa. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Valanafusp alfa. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Valanafusp alfa. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Valanafusp alfa. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Valanafusp alfa. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Valanafusp alfa. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Valanafusp alfa. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Valanafusp alfa. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Valanafusp alfa. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Valanafusp alfa. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Valanafusp alfa. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Valanafusp alfa. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Valanafusp alfa. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Valanafusp alfa. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Valanafusp alfa. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Valanafusp alfa. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Valanafusp alfa. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Valanafusp alfa. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Valanafusp alfa. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Valanafusp alfa. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Valanafusp alfa. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Valanafusp alfa. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Valanafusp alfa. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Valanafusp alfa. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Valanafusp alfa. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Valanafusp alfa. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Valanafusp alfa. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Valanafusp alfa. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Valanafusp alfa. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Valanafusp alfa. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Valanafusp alfa. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Valanafusp alfa. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Valanafusp alfa. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Valanafusp alfa. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Valanafusp alfa. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Valanafusp alfa. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Valanafusp alfa. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Valanafusp alfa. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Valanafusp alfa. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Valanafusp alfa. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Valanafusp alfa. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Valanafusp alfa. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Valanafusp alfa. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Valanafusp alfa. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Valanafusp alfa. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Valanafusp alfa. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Valanafusp alfa. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Valanafusp alfa. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Valanafusp alfa. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Valanafusp alfa. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Valanafusp alfa. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Valanafusp alfa. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Valanafusp alfa. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Valanafusp alfa. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Valanafusp alfa. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Valanafusp alfa. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Valanafusp alfa. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Valanafusp alfa. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Valanafusp alfa. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Valanafusp alfa. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Valanafusp alfa. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Valanafusp alfa. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Valanafusp alfa. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Valanafusp alfa. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Valanafusp alfa. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Valanafusp alfa. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Valanafusp alfa. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Valanafusp alfa. |